Think zebras, not horses
16 February 2011

The contingent value rights structured for Sanofi’s purchase of Genzyme helped seal the $20 bln deal. It shows how financial engineering can sometimes bridge divides. But the complexity of CVRs and their unpopularity among investors should limit their use to very special cases.